The National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of 39 medicines sold across India, revised the price of an anti-rabies injection, exempted a patented pneumococcal vaccine from price control for five years, and approved new brands of intravenous (IV) fluids under existing price orders. The decisions were issued through a series of Gazette notifications on July 8, 2026.

Most of the 39 medicines are combination drugs, meaning they contain two or more active ingredients in a single tablet or bottle. The list includes medicines for high blood pressure, diabetes, high cholesterol, bacterial infections and allergies, besides eye drops and Vitamin D3 supplements.

The list includes medicines for high blood pressure that combine drugs such as Amlodipine, Telmisartan and Bisoprolol Fumarate. It also covers cholesterol-lowering medicines combining Atorvastatin with either Ezetimibe or Clopidogrel, and diabetes medicines containing Sitagliptin, Metformin and Glimepiride.

Commonly used antibiotics, including Amoxicillin with Potassium Clavulanate, have been priced in both regular and dispersible tablet forms. The list also includes eye drops, a Vitamin D3 oral solution and Cetirizine syrup used to treat allergies.

The costliest medicine on the list is Tenecteplase injection, priced at more than ₹60,000 per vial. The drug is used in hospitals to dissolve blood clots during heart attacks.

An HIV treatment kit made by Emcure Pharmaceuticals has been priced at about ₹330, while an oral solution used in cancer treatment has been priced at around ₹60 per millilitre.

Manufacturers have been directed to sell these medicines at or below the prices fixed by the government, while retailers must display the price list prominently in their shops.

A tablet, an injection and an inhaler

The government also fixed the price of Calcium and Vitamin D3 tablets, commonly used to improve bone health. Each tablet containing 500 mg of calcium and Vitamin D3 has been priced at ₹8.93.

The price of anti-rabies immunoglobulin injection, given after exposure to rabies, usually following animal bites, has been revised from ₹112.19 to ₹119.48 per millilitre. The notification said the revision includes the Wholesale Price Index (WPI) impact of 0.64956% for 2026.

The NPPA also fixed a higher price for a nebuliser medicine made by Glenmark Pharmaceuticals that combines Glycopyrronium, Formoterol Fumarate and Budesonide in a single suspension. According to the notification, an expert committee reviewed the product over two meetings and found that it simplified treatment, reduced nebulisation time, lowered the risk of contamination and minimised medicine wastage.

The panel described the product as a modest improvement over existing treatments and recommended a 15% increase over the earlier price. The new price has been fixed at ₹56.35 per millilitre for a 2 ml pack. The revised price applies only to Glenmark and replaces the rate fixed for the company at the end of last year.

Exemption for a pneumococcal vaccine

The government has exempted Biological E Limited from price control for its Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX 14), which protects against pneumococcal disease—serious infections caused by the bacterium Streptococcus pneumoniae. These infections can lead to pneumonia, meningitis, bloodstream infections and ear infections, particularly in young children, older adults and people with weakened immune systems.

The exemption means the company will not have to follow a government-fixed ceiling price for the vaccine for the next five years. The notification noted that the company holds an Indian patent for the invention, titled “Multivalent Pneumococcal Conjugate Vaccine,” granted on July 8, 2021.

After reviewing the application, the pricing authority found that the company met the conditions for exemption under India’s drug pricing rules, which allow certain patented medicines to be kept outside price control.

Once the five-year exemption ends, the company will either have to align the vaccine’s price with the government-notified ceiling price or seek approval for its price at least three months before the exemption expires.

New brands added to IV fluid orders

The NPPA also allowed Sachin Parenteral Private Limited to market two brands—”Euro Head” and “Safe Port”—under prices that had already been approved earlier this year.

One approval covers intravenous (IV) fluid packs used to administer fluids through a drip, while the other covers Ringer Lactate, a solution commonly used to treat dehydration and blood loss in hospitals. In both cases, the company can market only the specified pack sizes at the prices already fixed for those categories.

Also read: West Bengal’s diabetes numbers are worse than India’s average. Here’s why